Id Counterfeit Pharmaceuticals with Portable Raman
Rigaku
Pfizer’s new $200m (€152m) research centre is up and running, bringing to an end the firm’s four year project to amalgamate its existing research facilities in St Louis, Missouri, US.
According to Pfizer’s website the facility will focus on the development of drugs for arthritis, osteoarthritis and inflammatory pain, making it part of the small molecule R&D division the firm will form when it completes the acquisition of Wyeth.
Don Frail, director of the Chesterfield site, told St Louis’ KWMU radio station that 250 researchers will move into the facility over the next two months as necessary validation work is completed.
He went on to say that eventually the facility will house around 1,200 Pfizer employees and that this central location will provide a collaborative environment stimulating innovation.
